[ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Jing Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, First Hospital of Jilin University, Changchun 130021, China. Hauptthemen laut MEDLINE: Glioma, Radioisotopes, Lutetium, Carbonic Anhydrase IX. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Department of Finance of Jilin Province, Guizhou Science and Technology Department, National Natural Science Foundation of China.
Abstract (Originalsprache)
Malignant glioma highly expresses carbonic anhydrase IX (CAIX). This study aimed to develop [177Lu]Lu-XYIMSR-01, a small-molecule therapeutic agent CAIX, to assess its potential for treating malignant glioma. [177Lu]Lu-XYIMSR-01 was synthesized by radiolabeling DOTA-XYIMSR-01 with 177Lu. In vitro assays were conducted to evaluate the affinity for U87MG tumor cells. The probe was injected via the tail vein into subcutaneous and orthotopic U87MG models for micro-SPECT/CT imaging. The survival rates of tumor-bearing mice were assessed after [177Lu]Lu-XYIMSR-01 injection by intratumoral in orthotopic models, including untreated controls and those treated with Temozolomide or combination therapy. After purification, the radiochemical yield of [177Lu]Lu-XYIMSR-01 was 86.47 ± 2.42%, with a radiochemical purity (RCP) of 99%. Its cell uptake in U87MG cells was 3.70 ± 0.57 ‰ AD/105 cells, significantly higher than that in HCT116 cells (0.68 ± 0.16 ‰ AD/105 cells, P = 0.001). In the biodistribution study, [177Lu]Lu-XYIMSR-01 uptake in U87MG tumors was 6.19 ± 1.37%ID/g, with a tumor/muscle ratio of 20.14 ± 3.24. In the orthotopic glioma model, local injection combined with Temozolomide significantly improved survival and inhibited tumor growth. The results indicate that [177Lu]Lu-XYIMSR-01 is a promising therapeutic molecular probe for targeting CAIX, and its combination with Temozolomide significantly enhances treatment outcomes for malignant glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology, First Hospital of Jilin University, Changchun 130021, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
- Department of Orthopedics, Guizhou Provincial People's Hospital, Guiyang 550002, China.
ORCID-Profile: Zhi Yang, Xianteng Yang
Förderung
- Department of Finance of Jilin Province
- Guizhou Science and Technology Department
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., He, C., Guo, R., Wen, L., Tao, J., Zhang, H., Huang, H., Zhu, H., Yang, Z., & Yang, X. (2025). [ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00041
Vancouver
Wang J, He C, Guo R, Wen L, Tao J, Zhang H, et al. [ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00041
BibTeX
@article{Wang2025,
author = {Wang, Jing and He, Chengxue and Guo, Rui and Wen, Li and Tao, Jinping and Zhang, Huimao and Huang, HaiFeng and Zhu, Hua and Yang, Zhi and Yang, Xianteng},
title = {[ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00041}
}
EUVIMED